Precision Diagnostics
AXINON® System, Using FDA-Cleared Technology
Numares Health develops advanced biomarker tests to diagnose and measure disease progression for conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases.
We use nuclear magnetic resonance (NMR) spectroscopy to quantify multiple biomarkers — known and newly discovered — from a single serum sample. Machine learning then identifies the few, specific metabolitesrelevant to diagnosis.
The AXINON® System, using FDA-cleared technology, is our core technology platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
AXINON® GFR(NMR) is a kidney function assay, available as a CE-labled in vitro diagnostic product in the EU.
Alex’ Story: Born with one kidney. What happens when it fails?
AXINON® HCC(NMR) is a liver cancer early detection test, currently in development.
Cardiology
AXINON® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.
AXINON® lipoFIT®: For cardiovascular risk assessment.
Available as a CE-labled in vitro diagnostic product in the EU
Nephrology
AXINON® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.
Available as a CE-labled in vitro diagnostic product in the EU
Hepatology
AXINON® HCC(NMR): Liver cancer early detection test.
In development
